Insights
R&D for new drugs to tackle AMR is a high-return investment for all EU member states
19 July 2024
Two recently-published papers predict high returns from a policy which incentivises the development of new antibiotics.
Around the World in HTAs: United States – Making HTA Great Again
11 June 2024
In this Insights series, Around the World in HTAs, we shed light on HTA around the world. In this edition, Chris Sampson and Dan Ollendorf take us to the United States.
Using Target Product Profiles (TPPs) to improve diagnostic testing for cancer
10 June 2024
Tackling cancer is a major global priority. Early detection and diagnosis can help patients get timely access to treatment and dramatically improve cancer outcomes. This relies, in part, on the effective diagnostic tests.
NICE at 25: Technology Appraisals – Faster Access to Modern Treatment?
1 May 2024
OHE celebrates NICE’s 25th anniversary through a series of insights explaining NICE’s first steps and discussing NICE’s present and future role.
NICE at 25: HTA Methods Guidelines – Evolution, not revolution
1 May 2024
OHE celebrates NICE’s 25 anniversary through a series of insights explaining NICE’s first steps and discussing NICE’s present and future role.
Plan For A New EU Pharmaceutical Legislation: What Will It Mean For Pharmaceutical Innovation?
12 April 2024
The European Commission and European Parliament have set out their proposals for a reformed EU pharmaceutical legislation which could substantially change the incentive ecosystem for the first time in 20 years.
Kahneman’s legacy in health economics
4 April 2024
Daniel Kahneman (1934 – 2024) was a Nobel Prize-winning psychologist known for his pioneering work in behavioural economics.
Rare Disease Day 2024: Why Do We Care About Rare?
29 February 2024
Rare Disease Day is observed on the last day of February every year, and today – February 29th – is truly the rarest day.
Looking Further Afield – What Can Health Economics Learn from the Environmental Economics Approach to Discounting?
1 February 2024
Discounting in economic evaluations presents challenges for therapies with high up-front costs and long-term benefits. We discuss how health economics can learn from debates occurring within environmental economics, where discounting poses similar challenges.